DOCSLIB.ORG

Repertoire Commente Des Medicaments 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Repertoire Commente Des Medicaments 2021 Introduction 1. Système cardio-vasculaire REPERTOIRE COMMENTE 2. Sang et coagulation DES MEDICAMENTS 3. Système gastro-intestinal 2021 4. Système respiratoire 5. Système hormonal 6. Gynéco-obstétrique 7. Système urogénital 8. Douleur et fièvre 9. Pathologies ostéo-articulaires 10. Système nerveux REPERTOIRE DES MEDICAMENTS 2021 11. Infections 12. Immunité 13. Médicaments antitumoraux 14. Minéraux, vitamines et toniques 15. Dermatologie 16. Ophtalmologie CBIP 17. Oto-Rhino-Laryngologie CENTRE BELGE 18. Anesthésie D’INFORMATION PHARMACOTHERAPEUTIQUE Mises à jour régulières sur www.cbip.be 19. Agents de diagnostic 20. Médicaments divers Sur www.cbip.be: le Répertoire avec mises à jour régulières et tableaux comparatifs des prix Index Abréviations Symboles alc. = alcoolique i.ventr. = intraventriculaire Prescription (voir aussi Intro.3.) amp. = ampoule i.vésic. = intravésical anti-Xa = anti-facteur Xa i.vitr. = intravitréen R/ soumis à prescription médicale auric. = auriculaire laryngophar. = laryngopharyngé (R/) soumis à prescription médicale ou “sur demande écrite du bucc. = buccal lib. = libération ou libéré patient” buv. = buvable liq. = liquide caps. = capsule m = mois Remboursement (voir aussi Intro.4.2.) cart. = cartouche max. = maximum a, b, c, cs, cx CFU = unité formant colonies médic. = médicamenteux : pour plus d’explications sur ces catégories de compr. = comprimé mEq = milliéquivalent remboursement, voir Intro.4.2. cons. = conservateur modif. = modifié cut. = cutané (M)U(I) = (million) unité (internationale) Remboursement selon le chapitre IV ou VIII, c.-à-d. dans la dent. = dentaire nas. = nasal plupart des cas uniquement après autorisation du médecin- disp. = dispersible nébul. = nébuliseur conseil de l’organisme assureur (contrôle a priori) dos. = dose opht. = ophtalmique Remboursement selon le chapitre II, c.-à-d. sans autorisation efferv. = effervescent or. = oral préalable du médecin-conseil de l’organisme assureur, mais émuls. = émulsion orodisp. = orodispersible avec un contrôle a posteriori endocerv. = endocervical oromuq. = oromuqueux J Intervention spéciale de l’INAMI pour les contraceptifs pour endotrach. = endotrachéobronchique orophar. = oropharyngé les femmes de moins de 21 ans enr. = enrobé p.artic. = périarticulaire épilés. = épilésionnel past. = pastille h Remboursement uniquement en milieu hospitalier éq. = équivalent pdr = poudre flac. = flacon p.dural. = péridural Chr Intervention spéciale de l’INAMI chez certains patients FTM = Formulaire Thérapeutique pellic. = pelliculé atteints de douleurs chroniques persistantes Magistral perf. = perfusion gastr. = gastrique p.j. = par jour Médicament “bon marché” (voir Intro.4.2. pour plus gastro-ent. = gastro-entéral p.neur. = périneural d’explications) gastro-résist. = gastro-résistant p.odont. = périodontal Médicament n’appartenant pas à la catégorie des gél. = gélule Posol. = posologie médicaments “bon marché” (voir Intro.4.2. pour plus gingiv. = gingival ppm = partie par million d’explications) glob. = globule prép. = préparation gran. = granulés press. = pressurisé Pharmacovigilance (voir aussi Intro.6.2.1.) prol. = prolongé gtts = gouttes Médicament pour lequel une attention particulière est i.artér. = intra-artériel RCP = Résumé des Caractéristiques du demandée en ce qui concerne les effets indésirables i.artic. = intra-articulaire Produit i.burs. = intrabursal récip. = récipient s Médicament pour lequel des « activités de minimisation des i.camér. = intra-camérulaire rect. = rectal risques » supplémentaires sont exigées (triangle orange sur le i.card. = intracardiaque resp. = respiration site web) i.cavern. = intracaverneux s.c. = sous-cutané Dopage i.cistern. = intracisternal s.conj. = sous-conjonctival (voir aussi Intro.3.) i.derm. = intradermique séc. = sécable Produit repris dans la liste WADA des substances interdites i.lés. = intralésionnel sem. = semaine dans le sport i.m. = intramusculaire ser. = seringue implant. = implantation s.muq. = sous-muqueux Produit qui n’est pas interdit mais pouvant donner un impr. = imprégné sol. = solution ou soluble contrôle anti-dopage positif infiltr. = infiltration solv. = solvant Insuffisance rénale (voir aussi Intro.6.1.2.) inhal. = inhalation SQ-T = unité de qualité standardisée inj. = injectable subling. = sublingual réduction de la dose ou contre-indication en cas instill. = instillation supp. = suppositoire d'insuffisance rénale sévère i.ocul. = intra-oculaire susp. = suspension réduction de la dose ou contre-indication déjà en cas i.oss. = intra-osseux transderm. = transdermique i.périt. = intrapéritonéal TU = unité de tuberculine d'insuffisance rénale modérée i.pleur. = intrapleural U.H. = usage hospitalier IR = indice de réactivité UIK = unité inactivatrice de la kallidi- irrig. = irrigation nogénase i.théc. = intrathécal urétr. = urétral i.tumor. = intratumoral vag. = vaginal i.utér. = intra-utérin i.v. = intraveineux REPERTOIRE COMMENTE DES MEDICAMENTS 2021 CBIP CENTRE BELGE D’INFORMATION PHARMACOTHERAPEUTIQUE Mises à jour régulières sur www.cbip.be II 34ème édition REPERTOIRE COMMENTE DES MEDICAMENTS 2021 Centre Belge d’Information Pharmacothérapeutique (Belgisch Centrum voor Farmacotherapeutische Informatie) asbl, agréée par l’Agence Fédérale des Médicaments et des Produits de Santé (AFMPS). Site Web: www.cbip.be ou www.bcfi.be Adresses de correspondance Rédaction (concernant le contenu des publications du CBIP) CBIP c/o Campus Heymans, Blok B, 1er étage Corneel Heymanslaan 10 9000 Gent e-mail: [email protected] Administration et problèmes techniques CBIP c/o Agence Fédérale des Médicaments et des Produits de Santé (AFMPS) Avenue Galilée 5/03 1210 Bruxelles Adresses e-mail: [email protected] (à propos des spé- Comité de rédaction cialités reprises dans le Répertoire Com- T. Christiaens (Universiteit Gent), et J.M. Malo- menté des Médicaments) teaux (Université Catholique de Louvain), rédac- [email protected] (pour les chan- teurs en chef gements d’adresse e-mail, les demandes M.H. Antoine (Université Libre de Bruxelles), de Répertoire; pour les étudiants, la distri- A. Baitar, G. Beuken (Société Scientifique de bution se fait par le département respon- Médecine Générale), D. Bijl, M. Bogaert (Universi- sable de leur faculté ou de leur école; les teit Gent), D. Boudry, W. Buylaert (Universiteit Gent), exemplaires ne sont pas envoyés indivi- G. De Loof (Domus Medica),M. De Maesschalck, duellement aux étudiants) P. De Paepe (Universiteit Gent), C. Devillers, B. [email protected] (à propos des Dhooghe, G. Goesaert, H. Habraken, L. Hamtiaux, aspects techniques du site Web et des G. Laekeman (Katholieke Universiteit Leuven), versions électroniques du Répertoire) I. Latour, H. Marsily, N. Mortier, T. Roisin (Centre Belge de Pharmacovigilance), J. Vandenhoven, A. Van Ermen, L. Vansnick (Association Pharma- ceutique Belge), C. Veys D/2021/15174/02 Editeur responsable: Thierry Christiaens © Les informations publiées dans le Répertoire Commenté des Médicaments ne peuvent pas être reprises ou diffusées Nekkersberglaan 31 sans mention de la source, et elles ne peuvent en aucun 9000 Gent cas servir à des fins commerciales ou publicitaires. III Table des matières Introduction ..............................................1 Intro 1. Élaboration du Répertoire .................................1 Intro 2. Guide d’utilisation du Répertoire .............................3 Intro 3. Médicaments génériques, biosimilaires et prescription en DCI .........10 Intro 4. Prix et modalités de remboursement .........................11 Intro 5. Répertoire en ligne et site Web du CBIP www.cbip.be ..............14 Intro 6. Bon usage des médicaments ..............................16 Intro 7. Intoxications médicamenteuses et urgences médicales .............29 1. Système cardio-vasculaire .................................33 1.1. Hypertension ........................................33 1.2. Angine de poitrine .....................................50 1.3. Insuffisance cardiaque ..................................54 1.4. Diurétiques .........................................58 1.5. Bêta-bloquants .......................................63 1.6. Antagonistes du calcium .................................69 1.7. Médicaments agissant sur le système rénine-angiotensine ...........73 1.8. Antiarythmiques ......................................82 1.9. Hypotension .........................................89 1.10. Troubles vasculaires artériels ..............................91 1.11. Veinotropes et capillarotropes .............................93 1.12. Hypolipidémiants ......................................94 1.13. Médicaments de l’hypertension pulmonaire ....................106 1.14. Alprostadil .........................................108 1.15. Médicaments pour stimuler la fermeture du canal artériel ...........108 1.16. Associations pour la prévention cardio-vasculaire ................109 2. Sang et coagulation .....................................111 2.1. Antithrombotiques ....................................111 2.2. Antihémorragiques ....................................131 2.3. Médicaments de l’hématopoïèse ...........................136 3. Système gastro-intestinal ................................139 3.1. Pathologie gastrique et duodénale ..........................139 3.2. Spasmolytiques ......................................148 3.3. Pathologie du foie, de la vésicule biliaire et du pancréas ............150 3.4. Antiémétiques .......................................152 3.5. Laxatifs ...........................................157 3.6.
Load more

Recommended publications
  • TACHOSIL (Fibrin Sealant Patch)
    Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research MEMORANDUM To: Craig Zinderman, MD, MPH Acting Director, Division of Epidemiology (DE) Office of Biostatistics and Epidemiology (OBE), Center for Biologics Evaluation and Research (CBER) Through: Meghna Alimchandani, MD Associate Director for Medical Policy, OBE, CBER From: Faith Barash, MD, MPH Medical Officer, Pharmacovigilance Branch Office of Biostatistics and Epidemiology (OBE) Center for Biologics Evaluation and Research (CBER) Subject: Safety and Utilization Review for the Pediatric Advisory Committee Applicant: Takeda Pharma A/S Product: TACHOSIL (Fibrin Sealant Patch) STN: 125351/279 Indication: TACHOSIL is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. Meeting Date: Pediatric Advisory Committee Meeting, September 2019 1 Contents 1 INTRODUCTION ................................................................................................................................ 3 1.1 Objective ...................................................................................................................................... 3 1.2 Product Description .................................................................................................................... 3 1.3 Regulatory
    [Show full text]
  • Monitoring International Trends Posted May 2016
    Monitoring International Trends posted May 2016 The NBA monitors international developments that may influence the management of blood and blood products in Australia. Our focus is on: Potential new product developments and applications; Global regulatory and blood practice trends; Events that may have an impact on global supply, demand and pricing, such as changes in company structure, capacity, organisation and ownership; and Other emerging risks that could potentially put financial or other pressures on the Australian sector. A selection of recent matters of interest appears below. Highlights include: BioMarin Pharmaceutical released preliminary data on its investigational gene therapy treatment for haemophilia A. (Section 1) Data on Bluebird bio’s gene therapy in severe sickle cell disease and transfusion- dependent β-thalassemia was discussed at the American Society of Gene & Cell Therapy Annual Meeting. (Section 1) Europe’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending an extension to the marketing authorisation for Baxalta’s subcutaneous immunoglobulin, HyQvia. (Section 2) NovoNordisk submitted to the US Food and Drug Administration (FDA) a Biologics License Application for its long-acting factor IX. (Section 2) The European Commission approved Swedish Orphan Biovitrum and Biogen’s recombinant factor IX Fc Fusion protein therapy. (Section 2) The FDA granted seven years of marketing exclusivity for CSL Behring's Coagulation Factor IX (Recombinant), Albumin Fusion Protein, with an extended dosing interval]. (Section 2) In Australia, the Therapeutic Goods Administration (TGA) approved a monoclonal antibody that reverses the anticoagulant effect of dabigatran in patients who require emergency surgery or have life-threatening bleeding.
    [Show full text]
  • WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T (51) International Patent Classification: SHENIA, Iaroslav Viktorovych [UA/UA]; Feodosiyskyy A61L 15/44 (2006.01) A61L 26/00 (2006.01) lane, 14-a, kv. 65, Kyiv, 03028 (UA). A61L 15/54 (2006.01) (74) Agent: BRAGARNYK, Oleksandr Mykolayovych; str. (21) International Application Number: Lomonosova, 60/5-43, Kyiv, 03189 (UA). PCT/UA20 16/0000 19 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2016 (15.02.2016) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, a 2015 01285 16 February 2015 (16.02.2015) UA PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, u 2015 01288 16 February 2015 (16.02.2015) UA SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors; and TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Effect of Chitosan Dextran Gel As a Haemostatic and Anti-Adhesion
    THE EFFECT OF CHITOSAN DEXTRAN GEL AS A HAEMOSTATIC AND ANTI ADHESION AGENT IN THE CENTRAL NERVOUS SYSTEM AND EVALUATION OF HAEMOSTATIC MECHANISM OF SKELETAL MUSCLE TISSUE Thesis submitted in March 2015 for The degree of Doctor of Philosophy In the University of Adelaide By Sukanya Rajiv, M.B.B.S, M.S The work described in this thesis was performed within The Department of Surgery Otolaryngology, Head and Neck Surgery, The University of Adelaide 1 Table of Contents TITLE PAGE________________________________________ 1 ABSTRACT________________________________________ 5 INTRODUCTION____________________________________________ 5 METHODS_________________________________________________ 5 RESULTS__________________________________________________ 7 CONCLUSION___________________________________________ 7 DECLARATION________________________________________ 9 PREFACE_____________________________________________ 10 ACKNOWLEDGEMENTS_______________________________ 11 CHAPTER 1 AIMS_____________________________________ 13 CHAPTER 2 INTRODUCTION_______________________________ 15 CHAPTER 3 NORMAL HAEMOSTASIS______________________ 21 BLOOD VESSEL/ ENDOTHELIAL CELL___________________________ 22 PLATELETS___________________________________________________ 25 COAGULATION CASCADE______________________________________ 27 INHIBITORS OF COAGULATION_________________________________ 28 FIBRINOLYTIC SYSTEM________________________________________ 29 COAGULATION SCREEN TESTS_________________________________ 30 CHAPTER 4 HEMOSTATIC TECHNIQUES IN CENTRAL NERVOUS SYSTEM___________________________________
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Management of Bleeding and Coagulopathy Following Major Trauma
    Spahn et al. Critical Care 2013, 17:R76 http://ccforum.com/content/17/2/R76 RESEARCH Open Access Management of bleeding and coagulopathy following major trauma: an updated European guideline Donat R Spahn1, Bertil Bouillon2, Vladimir Cerny3,4, Timothy J Coats5, Jacques Duranteau6, Enrique Fernández-Mondéjar7, Daniela Filipescu8, Beverley J Hunt9, Radko Komadina10, Giuseppe Nardi11, Edmund Neugebauer12, Yves Ozier13, Louis Riddez14, Arthur Schultz15, Jean-Louis Vincent16 and Rolf Rossaint17* Abstract Introduction: Evidence-based recommendations are needed to guide the acute management of the bleeding trauma patient. When these recommendations are implemented patient outcomes may be improved. Methods: The multidisciplinary Task Force for Advanced Bleeding Care in Trauma was formed in 2005 with the aim of developing a guideline for the management of bleeding following severe injury. This document represents an updated version of the guideline published by the group in 2007 and updated in 2010. Recommendations were formulated using a nominal group process, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) hierarchy of evidence and based on a systematic review of published literature. Results: Key changes encompassed in this version of the guideline include new recommendations on the appropriate use of vasopressors and inotropic agents, and reflect an awareness of the growing number of patients in the population at large treated with antiplatelet agents and/or oral anticoagulants. The current guideline also includes recommendations and a discussion of thromboprophylactic strategies for all patients following traumatic injury. The most significant addition is a new section that discusses the need for every institution to develop, implement and adhere to an evidence-based clinical protocol to manage traumatically injured patients.
    [Show full text]
  • Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020
    Medicines/pharmaceuticals of animal origin V3.0 November 2020 Medicines/pharmaceuticals of animal origin - This guideline provides information for all clinical staff within Hospital and Health Services (HHS) on best practice for avoidance of issues related to animal products. Medicines/pharmaceuticals of animal origin - V3.0 November 2020 Published by the State of Queensland (Queensland Health), November 2020 This document is licensed under a Creative Commons Attribution 3.0 Australia licence. To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au © State of Queensland (Queensland Health) 2020 You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health). For more information contact: Medication Services Queensland, Queensland Health, GPO Box 48, Brisbane QLD 4001, email [email protected] An electronic version of this document is available at https://www.health.qld.gov.au/__data/assets/pdf_file/0024/147507/qh-gdl-954.pdf Disclaimer: The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate
    [Show full text]
  • Therapeutic Options to Minimize Allogeneic Blood
    Santos AA, etREVIEW al. - Therapeutic ARTICLE options to minimize allogeneic blood Rev Bras Cir Cardiovasc 2014;29(4):606-21 transfusions and their adverse effects in cardiac surgery: A systematic review Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: A systematic review Opções terapêuticas para minimizar transfusões de sangue alogênico e seus efeitos adversos em cirurgia cardíaca: Revisão sistemática Antônio Alceu dos Santos1, MD; José Pedro da Silva1, MD, PhD; Luciana da Fonseca da Silva1, MD, PhD; Alexandre Gonçalves de Sousa1, MD; Raquel Ferrari Piotto1, MD, PhD; José Francisco Baumgratz1, MD DOI: 10.5935/1678-9741.20140114 RBCCV 44205-1596 Abstract Results: Treating anemia and thrombocytopenia, suspending Introduction: Allogeneic blood is an exhaustible therapeutic anticoagulants and antiplatelet agents, reducing routine phle- resource. New evidence indicates that blood consumption is ex- botomies, utilizing less traumatic surgical techniques with moderate cessive and that donations have decreased, resulting in reduced hypothermia and hypotension, meticulous hemostasis, use of topical blood supplies worldwide. Blood transfusions are associated and systemic hemostatic agents, acute normovolemic hemodilu- with increased morbidity and mortality, as well as higher hos- tion, cell salvage, anemia tolerance (supplementary oxygen and pital costs. This makes it necessary to seek out new treatment normothermia), as well as various other therapeutic options have options. Such options
    [Show full text]
  • Management of Bleeding Associated with Malignant Wounds
    JOURNAL OF PALLIATIVE MEDICINE Volume 15, Number 8, 2012 Case Discussions ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2011.0286 in Palliative Medicine Feature Editors: Eva H. Chittenden and Craig D. Blinderman Management of Bleeding Associated with Malignant Wounds Katherine Recka, M.D., Marcos Montagnini, M.D., and Caroline A. Vitale, M.D. Abstract Bleeding malignant wounds in palliative care patients can be anxiety-provoking for patients, their caregivers, and healthcare providers, and can be difficult to manage. We present the case of a 60-year-old man with a bleeding neck wound due to squamous cell carcinoma of the hypopharynx admitted to our inpatient palliative care unit. Management of bleeding included local wound care measures and psychosocial support for the patient and his wife. We review therapeutic approaches to managing bleeding malignant wounds with the aim of providing clinically useful information. Introduction On admission, physical examination revealed a cachectic man with a large ulcerated wound along the angle of his jaw leeding associated with malignant wounds can be from just below his left ear to his tracheostomy. The inferior difficult to manage in all settings, but particularly in aspect of the wound approached the left clavicle. The wound B settings in which goals of care center on comfort and quality of had multiple areas of punctuate hemorrhages and required life. We discuss a challenging case of a patient with a persis- frequent dressing changes to absorb the bleeding. There was no tent bleeding malignant neck wound arising from a stage IV significant odor. His tracheostomy secretions were thick and supraglottic squamous cell carcinoma.
    [Show full text]
  • Beverly, A., Ong, G., Wilkinson, KL, Doree, C., Welton, NJ, & Estcourt, LJ
    Beverly, A., Ong, G., Wilkinson, K. L., Doree, C., Welton, N. J., & Estcourt, L. J. (2019). Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: A systematic review and network meta analysis. Cochrane Database of Systematic Reviews, 2019(9), [CD013427]. https://doi.org/10.1002/14651858.CD013427 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD013427 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Collaboration at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013427/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Cochrane Database of Systematic Reviews Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta- analysis (Protocol) Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ. Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013427. DOI: 10.1002/14651858.CD013427. www.cochranelibrary.com Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis (Protocol) Copyright © 2019 The Cochrane Collaboration.
    [Show full text]